Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Drug-eluting stents and perioperative risk - more than matters of the heart?

Lanckohr C, Torsello G, Scheld H, Schieffer B, Theilmeier G.

Vasa. 2012 Nov;41(6):410-8. doi: 10.1024/0301-1526/a000231. Review.


Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.


Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.

Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL.

Cardiovasc Ther. 2013 Aug;31(4):193-200. doi: 10.1111/j.1755-5922.2012.00319.x.


Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators..

JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008.


First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013.


Drug-eluting stent thrombosis.

Stähli BE, Camici GG, Tanner FC.

Ther Adv Cardiovasc Dis. 2009 Feb;3(1):45-52. doi: 10.1177/1753944708096280. Review.


Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.

Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C; ZEUS Investigators..

J Am Coll Cardiol. 2015 Mar 3;65(8):805-15. doi: 10.1016/j.jacc.2014.11.053.


New concepts in the design of drug-eluting coronary stents.

Garg S, Bourantas C, Serruys PW.

Nat Rev Cardiol. 2013 May;10(5):248-60. doi: 10.1038/nrcardio.2013.13. Review.


Contemporary approaches to perioperative management of coronary stents and to preoperative coronary revascularization: a survey of 374 interventional cardiologists.

Khair T, Garcia B, Banerjee S, Brilakis ES.

Cardiovasc Revasc Med. 2011 Mar-Apr;12(2):99-104. doi: 10.1016/j.carrev.2009.09.007.


Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.

Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL, Kastrati A.

JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74. doi: 10.1016/j.jcin.2013.06.015.


Bare-metal stent versus drug-eluting stent in large coronary arteries: meta-analysis of randomized controlled trials.

Geng DF, Meng Z, Yan HY, Nie RQ, Deng J, Wang JF.

Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1087-94. doi: 10.1002/ccd.24599.


Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.

Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R; CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators..

JACC Cardiovasc Interv. 2009 Apr;2(4):303-9. doi: 10.1016/j.jcin.2008.12.013.


Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.

Gogas BD, Garcia-Garcia HM, Onuma Y, Muramatsu T, Farooq V, Bourantas CV, Serruys PW.

JACC Cardiovasc Interv. 2013 Mar;6(3):211-21. doi: 10.1016/j.jcin.2013.01.132. Review.


Stent thrombosis and drug-eluting stents.

Takayama T, Hiro T, Hirayama A.

J Cardiol. 2011 Sep;58(2):92-8. doi: 10.1016/j.jjcc.2011.07.003. Review.


The excel stent: a good DES, but can we really stop clopidogrel after 6 months?

Margolis JR.

JACC Cardiovasc Interv. 2009 Apr;2(4):310-1. doi: 10.1016/j.jcin.2009.01.005. No abstract available.


Significant differences between vascular and nonvascular surgeons in the perioperative management of antiplatelet therapies in patients with coronary stents.

Kilic A, Sultan IS, Arnaoutakis GJ, Black JH 3rd, Reifsnyder T.

Ann Vasc Surg. 2015 Apr;29(3):526-33.e2. doi: 10.1016/j.avsg.2014.09.031.


Use of drug-eluting balloon coronary intervention prior to living donor kidney transplantation.

Kammerer T, Beiras-Fernandez A, Rehm M, Stangl M, Guba M, Kupatt-Jeremias C, Weis F.

BMC Cardiovasc Disord. 2014 Sep 1;14:112. doi: 10.1186/1471-2261-14-112.


Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.

Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ.

JACC Cardiovasc Interv. 2008 Oct;1(5):494-503. doi: 10.1016/j.jcin.2008.06.011.

Items per page

Supplemental Content

Support Center